IMPACT OF CASE DETECTION AND COVID-19-RELATED DISRUPTIONS ON TUBERCULOSIS

IN VIETNAM: A MODELLING ANALYSIS

Viet Long Bui, Romain Ragonnet, Angus E. Hughes, David S. Shipman, Emma S. McBryde,

Binh Hoa Nguyen, Hoang Nam Do, Thai Son Ha, Greg J. Fox, James M. Trauer

Corresponding author:

Viet Long Bui, School of Public Health and Preventive Medicine, Monash University

553 St Kilda Road

Melbourne, VIC 3004, Australia

Email: viet.bui1@monash.edu

Running title: COVID-19's impact on TB detection in Viet Nam

IMPACT OF CASE DETECTION AND COVID-19-RELATED DISRUPTIONS ON TUBERCULOSIS

IN VIETNAM: A MODELLING ANALYSIS

Viet Long Bui[1,*], Romain Ragonnet[1], Angus E. Hughes[1], David S. Shipman[1], Emma S.

McBryde[2], Binh Hoa Nguyen[3,4], Hoang Nam Do[3,4], Thai Son Ha[5], Greg J. Fox[6,7], James M.

Trauer[1]

[1] School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria,

Australia

[2] Centre for Clinical Research, The University of Queensland, Brisbane, Queensland, Australia

[3] National Lung Hospital, Ha Noi, Vietnam

[4] National Tuberculosis Program, Ha Noi, Vietnam

[5] Administration of Medical Services, Ministry of Health, Ha Noi, Vietnam

[6] Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia

[7] The Woolcock Institute for Medical Research, Glebe, New South Wales, Australia

* Corresponding author, email: viet.bui1@monash.edu

Word count: Main text: 3490, Abstract: 240

Running title: COVID-19's impact on TB detection in Viet Nam

Summary: COVID-19 disrupted TB detection in Vietnam, leading to long-term increases in

incidence and mortality. Modelling suggests improved case-finding could avert a sizeable portion of

new infections and deaths, but sustained investment is essential to improve TB prevention and care.

44 **ABSTRACT**

Background

Vietnam, a high-burden tuberculosis (TB) country, experienced marked declines in TB notifications during the COVID-19 pandemic. We assessed the impact of pandemic-related disruptions on TB case detection and transmission using a dynamic transmission model calibrated to local demographic and epidemiological observations.

Methods

We developed an age-structured compartmental TB transmission model to estimate COVID-19's impact on TB in Vietnam. Four model assumptions reflecting reductions in detection and/or transmission were calibrated to notification data, with the best-fitting assumption used for future projections and to evaluate the effects of enhanced case detection scenarios.

Results

COVID-19 significantly disrupted TB services in Viet Nam, resulting in an estimated 2,000 additional TB episodes (95% credible interval [CrI]: 200-5,100) and 1,100 TB-related deaths (95%CrI: 100-2,700) in 2021. By 2035, the cumulative impact of these disruptions could reach 22,000 additional TB episodes (95%CrI: 2,200-63,000) and 5,900 deaths (95%CrI: 600-16,600) by 2035. We predicted two hypothetical scenarios of enhancing TB case detection. Under the ambitious scenario, enhancing TB case detection could mitigate these potential impacts by preventing 17.8% of new TB episodes (95%CrI: 13.1%-21.9%) and 34.2% (95%CrI: 31.5%-37.0%) of TB-related deaths by 2035, compared to no enhancement.

Conclusions

COVID-19-related disruptions have hindered TB detection in Vietnam, likely causing long-term increases in new TB episodes and deaths. However, the uncertainty around these effects is considerable. Sustained investment in diagnostics, system resilience, and patient-centric policies have the potential to achieve benefits that are substantially larger than these pandemic-related setbacks.

70   **Keywords:** Mycobacterium tuberculosis, COVID-19 pandemic, Case detection, Transmission

71   dynamic model, compartmental model.

INTRODUCTION

Tuberculosis (TB), the disease caused by the bacterium *Mycobacterium tuberculosis (M.tb)*,

remains a critical global public health challenge [1]. Vietnam is among the 30 high TB burden

countries designated by the World Health Organization (WHO), with an estimated incidence of 182

per 100,000 population in 2023 [1]. Despite decades of programmatic effort and sustained political

commitment, TB control in Vietnam remains a challenge due to a combination of delayed case

detection, underdiagnosis, and gaps in access to care.

The COVID-19 pandemic appears to have severely disrupted global TB prevention and care,

causing significant declines in TB notifications in high-burden countries [2–4]. The WHO reported

an 18% global decline in TB notifications in 2020, with an estimated 200,000–400,000 additional TB

deaths [2, 5]. WHO TB burden estimates are primarily based on static models using notification

trends, prevalence surveys, or expert adjustments, and only recently incorporated dynamic

transmission models for a limited number of countries significantly affected by COVID-19 [6], which

may not be the optimal approach to predicting long-term TB impact estimates. The reduction in TB

notifications may be attributable to healthcare disruptions, resource diversion, reduced healthcare-

seeking behavior or some combination of these factors. However, COVID-19 measures like mask-

wearing and social distancing may also have reduced TB transmission, which are not accounted for

in WHO's early estimates [5]. Vietnam implemented several stringent public health and social

measures (PHSMs) in the region, including aggressive contact tracing, lockdowns, and mobility

restrictions, particularly during 2021 [7]. Given these complex and context-specific dynamics, a

dynamic modelling approach is essential to accurately quantify the impact of COVID-19 on *M.tb*

transmission and TB case detection in Vietnam.

In this study, we developed a dynamic TB transmission model calibrated to Vietnam's demographic

and epidemiological data to simulate *M.tb* transmission dynamics, estimate the impact of COVID-19

on *M.tb* transmission, and project the effects of hypothetical scenarios involving enhanced case

finding.

METHODS

1. Model structure

We developed a compartmental model comprising six compartment types - Susceptible (S),

Early latent (E), Late latent (L), Active TB or infectious (I), Treatment (T), and recovered (R) - to

represent different TB-related infection and disease states, using a similar conceptual approach and

assumptions as our previously published model [8]. The model was stratified by age, BCG

vaccination, and clinical forms of TB, categorized into three clinical severity groups, which we

termed smear-positive TB (SPTB), smear-negative TB (SNTB), and extrapulmonary TB (EPTB).

These groups are defined primarily by differences in natural history and infectiousness, with SPTB

patients characterized by a more rapid disease progression and high infectiousness. By contrast,

SNTB represents a more benign disease course with partial infectiousness, while EPTB is

considered non-infectious. A detailed description of the model structure and all associated methods

are provided in the Supplemental Material.

The reduction in TB notifications during the COVID-19 pandemic could plausibly be attributable to

reduced case detection, decreased transmission, or both. To model these effects, we considered

four candidate assumptions: Assumption 1, the COVID-19 pandemic had no impact on either TB

detection or transmission; Assumption 2, only case detection was reduced, reflecting the decline in

healthcare access, while TB transmission remained unaffected; Assumption 3, only TB transmission

was reduced, with public health and social measures (PHSMs) limiting transmission, but with case

detection continuing unaffected; Assumption 4, both case detection and TB transmission were

reduced, incorporating the effects of both PHSMs and healthcare disruptions.

Table S2 (Supplementary Material) presents model parameters. One of the key parameters

in our model was the rate of commencing treatment for active TB, which governs the transition of

individuals from (I) to (T). This rate is the reciprocal of the average time from developing active TB

to first presentation and treatment initiation under the National TB Program (NTP). The average

time from developing active TB to first presentation for care and treatment initiation reflects delays

attributable to the patient, provider, and health system factors, which can each contribute to delayed

diagnoses. We used a smooth transition function that gradually increased with the historical

improvements in the availability of TB diagnostics and treatments over the pre-pandemic period.

In our model, the impact of COVID-19 on *M.tb* transmission and case detection were incorporated

through the use of reduction factors with minimally informative uniform priors, ranged from 0.01 to

0.90. These multipliers gradually declined from 2020 to 2021, before returning to baseline by 2022.

Under Assumptions 2 and 4, reductions affected treatment initiation; under Assumptions 3 and 4,

they applied to contact rate. In Assumption 4, transmission and detection reductions were

separately parameterized and calibrated to reflect distinct effect of the disruption.

We calibrated our model using the best available empirical data specific to Vietnam, including the

national population size [9], TB notifications and the proportion of pulmonary TB among these

notifications [10], and the prevalence of bacteriologically-confirmed and of SPTB among adults

from the second national TB prevalence survey [11, 12] (Table S3, Supplementary Materials). The

combined modelled prevalence of SPTB and SNTB was calibrated to match the bacteriologically-

confirmed prevalence reported in the survey. We compared our model's independent estimates of

TB incidence and mortality with WHO's estimates to support the plausibility of our projections.

The best assumption regarding COVID-19 impacts on *M.tb* transmission and case detection was

identified by comparing the expected log pointwise predictive density Watanabe-Akaike Information

Criterion (EPLD-WAIC) values across four scenarios, with less negative values indicating better

predictive performance [13].

3. Future projections

Using the best-performing assumption, which captured the sharp COVID-19-related decline

in TB notifications, as the '*status-quo'* scenario, we projected new TB episodes and TB-related

deaths from 2025 to 2035, and compared these outcomes with a counterfactual scenario in which

COVID-19 had no impact on *M.tb* transmission and TB case detection. Additionally, we assessed

the potential effects of enhanced case detection scenarios, simulating two- and five-fold increases

in TB treatment initiation rates by 2035. For each scenario, we estimated the number of new TB

episodes and TB-related deaths averted.

4. Software

We used *summer*, a Python-based epidemiological modelling framework [14], and

performed model calibration using PyMC-based DEMetropolisZ Bayesian inference algorithm [15].

Our model development, optimization, and calibration followed a pipeline equivalent to that detailed

in [16]. The code used for the analyses is accessible in a GitHub repository at:

https://github.com/vlbui/tbdynamics.

RESULTS

1. Calibration results

Comparison of candidate assumptions

All four assumptions closely matched the total population and the prevalence of TB among

adults, as shown in Figures S3 and S4 (Supplementary Material). However, the fit varied when

comparing the actual number of TB notifications to the equivalent model output. Figure 2 shows this

comparison under our four candidate assumptions regarding the effect of COVID-19 on *M.tb*

dynamics. Among the candidate assumptions, Assumption 2, which assumed reduced TB detection

during the COVID-19 pandemic, best fit the sharp decline in TB notifications in 2021, slightly

outperforming Assumption 4 (reductions in both detection and transmission) based on EPLD-WAIC

(Table S4, Supplementary Material). In contrast, Assumption 1 (no COVID-19 impact) and

Assumption 3 (reduced transmission only) fit the data less well.

Based on this analysis, we selected Assumption 2 as our primary model for the following in-depth

examination of *M.tb* dynamics in Vietnam. Figure 3 illustrates the comparison between calibration

targets and other epidemiological estimates not included in our calibration algorithm that we

considered for validation. Figure S5 presents model outputs derived from 50 randomly accepted

model runs.

Table S5 (Supplementary Material) details the posterior estimates and calibration metrics for the

calibrated parameters of our preferred candidate model. The algorithm demonstrated good chain

convergence, as evidenced by each parameter's Gelman-Rubin statistic ($\hat{R}$) being below 1.05.

Figure S6 (Supplementary Material) shows the trace plots for each parameter, illustrating their

convergence and stability throughout calibration. Figure S7 (Supplementary Material) overlays

posterior distributions on the corresponding priors of the calibrated parameters. The posterior

estimate for the reduction of COVID-19 on TB detection was 0.33 with 94% high density interval

ranging from 0.01 to 0.68. Figure S8 (Supplementary Material) shows how the posterior

distributions for the natural history parameters translate into the more epidemiologically intuitive

quantities of disease duration and case fatality rate for SPTB and SNTB.

Our calibration algorithm simulated a peak in adult pulmonary TB prevalence that began to decline

from around 1986, coinciding with the establishment of the NTP. By 2017, the model predicted an

adult pulmonary TB prevalence of 326 per 100,000 populations (95%CrI: 264–387), closely

matching our prevalence survey target, which estimated bacteriologically-confirmed TB among

adults at 322 (confidence interval – CI: 260–399) per 100,000 in 2017 [11].

We estimated TB incidence in 2022 at 156,000, equivalent to 160 per 100,000 population (95%CrI:

122-218), which closely matches the WHO's 2022 estimate of 176 per 100,000 (95%CI: 121–251,

not used as a calibration target) [10]. We estimated that approximately 18,000 (18 per 100,000)

people have died from TB each year since 2010. Our modelled prevalence of adult SPTB aligned

closely with the results of the 2007 prevalence survey (90 per 100,000, 95%CrI: 53-153, compared

to 99 per 100,000, 95%CI: 78-125) [17], but was higher than the 2017 survey results (63 per

100,000, 95%CrI: 32-119, compared to 46 per 100,000, 95%CI: 32-68) [11]. Figure S9

(Supplementary Material) illustrates the proportion of people with active TB originating from the

early latent class, highlighting that 50% or more of these cases were due to early progression and

therefore recent transmission throughout most of the recent simulation period. A minor increase in

the proportional contribution of recent transmission was observed in 2021 during the COVID-19

pandemic. The modelled prevalence of latent TB infection (LTBI) in 2019 was 45% of the total

population (95%CrI: 39%-51%). This aligns closely with the estimate from Ding et al. [18], which

places the LTBI prevalence at 43.75% of the population. Figure S10 (Supplementary Material)

presents the estimated new number of children developing TB per year. The model estimates that in

2023, approximately 26,800 children (95%CrI: 15,500–42,000) developed TB, accounting for 16%

of total incidence – somewhat higher than the global level (12%) estimated by the WHO [19] and

the figure of at least 7,800 previously mentioned by WHO for Vietnam [20]. In 2021, under

Assumption 2, TB incidence rose by 3.1% in children compared to 1.8% in adults. Figure S11

(Supplementary Material) shows the proportions of the population by compartment based on results

from the maximum likelihood run.

Figure S12 (Supplementary Material) shows the estimated increasing profile of the rate of

commencing treatment over time, The rise began around 1986, coinciding with the establishment of

the NTP and accelerated sharply in the late 1990s following DOTS implementation [20]. The

median case detection proportion stabilized at around 0.6 from 2010 onwards, which can be

interpreted as meaning that about 60% of new people with active TB were successfully detected

and commenced treatment. Specifically, we estimated a 33% reduction in the rate of commencing

treatment, during COVID-19, resulting in a 0.43-year (equivalent to 23 weeks) increase in the time

to active TB onset to treatment.

2. Future projections

Figure 4 illustrates how the COVID-19-related health system effects may contribute to impeding future TB control efforts under Assumption 2, in comparison with a counterfactual scenario that COVID-19 had no effect on TB notifications. In 2021, we estimated 2,000 additional TB episodes (95%CrI: 200–5,100) and 1100 additional TB deaths associated with the effects of COVID-19 (95%CrI: 100–2,700). By 2035, the cumulative annual burden could rise by 22,000 TB episodes (95%CrI: 1,900–63,000) and 5,900 more deaths (95%CrI: 600–16,600). Figure S13 (Supplementary Material) shows the projected impact of the COVID-19 on cumulative TB episodes and TB-related deaths from 2021 to 2035 - under Assumption 2 and 4, compared to a counterfactual scenario with no COVID-19 effect on notifications and *M.tb* transmission. Figure S14 (Supplementary Material) presents estimates of the cumulative number of new TB episodes plotted against key model parameters, illustrating how variations in these parameters correlated with projected outcomes.

In 2024, we estimated the average delay to diagnosis and treatment for a person with TB at 1.80 years, such that our scenarios are equivalent to reducing the delay to 0.9 years (47 weeks) with a 2-fold increase, and to 0.36 years (19 weeks) with 5-fold in rate of commencing treatment. Our projections of the results of these scenarios are presented in Figure 5. Compared to a *'status quo'* projection, enhanced case detection by increasing the rate of commencing care 5-fold could prevent approximately 434,000 (95%CrI: 250,000–692,000) new TB episodes, representing a 17.8% reduction (95%CrI: 13.1%-21.9%). Additionally, this scenario may avert 110,000 (95%CrI: 69,000–170,000) TB-related deaths, equivalent to 34.2% (95%CrI: 31.5%-37.0%) of all TB-related deaths over the coming decade. Notably, enhancing TB case detection may have an even greater impact on reducing TB-related mortality.

DISCUSSION

Our results show that the decline in TB detection during COVID-19 was primarily responsible for the sharp drop in TB notifications in Vietnam in 2021. This disruption is projected to result in long-term

increases in TB incidence and mortality, extending long beyond the period of disruption. However,

enhancing case detection could substantially mitigate these long-term impacts and accelerate

progress by reducing both incidence and mortality in the years following the pandemic. The novelty

of our study lies in the integration of dynamic transmission modeling with a flexible, modular

framework built using open-source softwares. Our approach allows for the simulation of pandemic-

related disruptions and future intervention scenarios, while supporting reproducibility and

adaptability [16].

The close alignment between modelled outputs and calibration targets demonstrates our model's

capacity to integrate multiple key observations reflecting TB burden with empirically derived natural

history parameters. We found that COVID-19 was associated with significant reductions in TB

detection, which poses a serious threat to long-term TB control efforts and aligns with findings from

other studies [21, 22]. However, Vietnam has adapted its policies in light of the lessons of the

COVID-19 pandemic and is working to enhance TB detection, focusing on decentralized services In

response to COVID-19, Vietnam has strengthened TB detection through decentralized services and

the 'Double X' strategy - combining chest radiography with GeneXpert - to improve early diagnosis

among vulnerable populations [23–25]. Continuing and expanding these programs may further

strengthen TB prevention and care, and mitigate long-term disruptions to TB control efforts.

The assumption incorporating reduced case detection aligned most closely with observed trends,

suggesting that COVID-19-related disruptions likely delayed TB diagnosis and treatment, leading to

fewer reported cases. While we cannot exclude that reduced contact may have contributed slightly,

the marked dip in case detection likely had a greater impact. The resulting backlog of undiagnosed

cases may continue to drive transmission.

The modelled delay from active TB onset to treatment can be interpreted as being exponentially

distributed with an average time to treatment of approximately 1.80 years, implying that many

people with TB remain undetected. This delay may appear higher than prior studies which reported

median diagnostic delays of 28 days in low- and lower-middle-income countries and 10 days in

upper-middle-income countries [26]. In high-endemic areas, delays often exceeded 120 days,

influenced by gender, rural residence, and health system inefficiencies [26, 27]. Variation in the

definition of first healthcare-seeking behavior further complicates comparisons, with definitions

ranging from visits to qualified providers to contact with the NTP [26]. The long delay can be partly

explained by the high prevalence and prolonged disease duration of SNTB. Despite advances in

molecular diagnostics, SNTB remains difficult to detect due to mild or absent symptoms [28].

The wide uncertainties in our projections reflect the fact that disruptions to TB case detection are

not directly measurable. Surveillance systems report only diagnosed cases, offering no visibility into

those who developed TB but were never detected or treated. As a result, the extent of missed or

delayed diagnoses during the pandemic must be inferred indirectly, contributing to the uncertainty in

estimation and future projection. Even so, these uncertainty ranges can guide policy. Policy-makers

should act on the median estimate but remain prepared for worse-case outcomes. Interventions

that are beneficial across all scenarios - such as expanded case-finding and improved diagnostic

access - should be prioritized. These findings highlight the urgent need to restore and strengthen

TB detection systems to mitigate long-term consequences, which requires sustained investment

and commitment. Future disruptions - whether pandemics or other crises - could further jeopardize

TB prevention and care.

Our study has limitations stemming from data availability and from uncertainties in TB epidemiology

and natural history. First, the model candidates were calibrated to the best available observed data,

including TB notifications data from the NTP and results from the national prevalence survey.

However, TB notifications may still be affected by incomplete capture of treated cases in

surveillance data or false-positive diagnoses. This limitation is particularly pronounced in children,

for whom diagnosis is more challenging and bacteriological confirmation rates are low, such that

current approaches may not fully capture the true disease burden in this population. Additionally,

changes in case definitions over time, driven by the shift from smear microscopy to more sensitive

microbiological diagnostics, may influence trends in notifications and complicate interpretation of

historical data.

Second, while recent research provides estimates for progression rates from LTBI to active TB,

LTBI reactivation remains difficult to observe [29, 30]. We relied on several estimates from low-

burden settings or from the pre-chemotherapy era that may not be fully applicable to the context of

Vietnam. The difficulty in conducting longitudinal studies in high-burden areas further limits the

precision of our estimates, potentially affecting the generalizability of our findings [31]. Despite this,

these estimates aligned well with observed data, and our infection natural history parameters were

empirically grounded, providing greater confidence than unsubstantiated assumptions such as a 5-

10% lifetime risk [30]. Uncertainties in input parameters likely contributed to the wide range of future

projections. We conceptually aligned our natural history categories with the historical "open" vs.

"closed" TB distinction - roughly corresponding to more infectious, symptomatic (SPTB) and less

infectious or extrapulmonary forms. While this is imprecise and may not correspond directly to

smear-based diagnostic status, this mapping broadly reflects current clinical understanding and

incorporates some heterogeneity in disease forms. The difficulty in conducting longitudinal studies

in high-burden areas further complicates the precision of these estimates [31]. The major

community-wide active case finding trial in Ca Mau province [32] provides opportunities for better

understanding TB epidemiology in Vietnam and our modelling analysis can be considered in this

context. The significant prevalence reduction observed during the trial period may suggest early

progression may contribute even more to people with TB than late reactivation and our model

estimated. This potential underestimation highlights an important area for future research to further

refine *M.tb* transmission dynamics.

Third, our model implemented a synthetic social contact matrix from 2007, and an updated matrix

would more accurately reflect current transmission dynamics, considering changes in social

behavior, contact patterns, and demographics. The matrix reflects average population contact

patterns but may overlook setting-specific transmission, such as within households or close-

proximity transmission during COVID-19 quarantine.

Fourth, although we assumed that the average delay to diagnosis and treatment initiation would not

change over the next ten years in our *"status-quo"* scenario, future changes - such as expansion of

NTP capacity, which could shorten this delay, or reductions in funding, which could compromise

treatment coverage - may alter this trajectory. Moreover, while important, addressing drug-resistant

TB was beyond the scope of this study.

Our study's strengths include our calibration approach, which harnessed open-source software and

successfully captured key indicators of the epidemic while also reflecting uncertainties around key

input parameters. The model was informed by multiple relevant data streams, including results from

the recent TB national survey. This allowed us to replicate the local TB burden and ensure that

historical trends in case detection were reflected through TB notifications. Although the model was

not calibrated to WHO's estimates of TB incidence and mortality - given they are derived from

modelling rather than surveillance - our results closely align with those estimates. Our pipeline can

simulate a broad range of directly transmitted pathogens, enables accurate, transparent with built-in

support for calibration and uncertainty analysis [16].

CONCLUSIONS

Our study underscores the significant impact of COVID-19-related disruptions on TB case detection

in Vietnam, leading to a backlog of undiagnosed people with TB that could sustain transmission for

years. However, these impacts may be mitigated by enhancing case detection activities, which can

improve early detection and reduce transmission risks. Any major disruption now or into the future -

whether due to another pandemic, other public health crises - could further exacerbate TB

prevention and care challenges. Addressing these risks requires sustained investment in diagnostic

capacity, healthcare system resilience, and proactive policies to mitigate the long-term

consequences of such disruptions on TB prevention and care. Although we initially hypothesised

that COVID-19 disruptions might provide insights into the underlying dynamics of the TB epidemic,

they ultimately revealed the considerable uncertainty in assessing TB burden, which remains largely

inferred from a single annual notification count. to mitigate the long-term consequences of such

disruptions on TB prevention and care.

DECLARATIONS

Ethics approval and consent to participate: Not applicable, as this study involves modeling and does not include human participants or identifiable data.

Availability of data and materials: The data supporting this article and the code used for the analyses are accessible in a GitHub repository at: https://github.com/vlbui/tbdynamics.

Competing interests: The authors declare that they have no competing interests.

Author Contributions

Viet Long Bui: Conceptualization, Methodology, Software, Data Curation, Formal analysis, Writing-Original draft preparation; Software; Writing- Reviewing and Editing; **Romain Ragonnet:** Conceptualization, Methodology, Software, Validation, Formal analysis, Writing- Reviewing and Editing; **Angus E. Hughes:** Methodology, Writing- Reviewing and Editing; **David S. Shipman:** Software; **Emma S. McBryde:** Writing- Reviewing and Editing; **Binh Hoa Nguyen :** Writing-Reviewing and Editing; **Hoang Nam Do:** Writing- Reviewing and Editing; **Thai Son Ha:** Writing-Reviewing and Editing; **Greg J. Fox:** Conceptualization, Data Curation, Methodology, Writing-Reviewing and Editing; **James M. Trauer:** Conceptualization, Methodology, Software, Validation, Formal analysis, Writing- Reviewing and Editing, Supervision.

Acknowledgements: Viet Long Bui is a recipient of a postgraduate scholarship from Monash University**.** James M. Trauer is the recipient of a Discovery Early Career Fellowship from the Australian Research Council (DE230100730). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Corresponding author: Viet Long Bui, School of Public Health and Preventive Medicine, Monash University, Melbourne, VIC, Australia. email viet.bui1@monash.edu.

REFERENCES

1. World Health Organization. Global Tuberculosis Report 2024. Geneva.

2. Dheda K, Perumal T, Moultrie H, Perumal R, Esmail A, Scott AJ, et al. The intersecting pandemics of tuberculosis and COVID-19: population-level and patient-level impact, clinical presentation, and corrective interventions. Lancet Respir Med. 2022;10:603–22.

3. Villiers AK de, Osman M, Struchiner CJ, Trajman A, Tumu D, Shah VV, et al. Tuberculosis healthcare service disruptions during the COVID-19 pandemic in Brazil, India and South Africa: A model-based analysis of country-level data. PLOS Glob Public Health. 2025;5:e0003309.

4. Surendra H, Elyazar IRF, Puspaningrum E, Darmawan D, Pakasi TT, Lukitosari E, et al. Impact of the COVID-19 pandemic on tuberculosis control in Indonesia: a nationwide longitudinal analysis of programme data. Lancet Glob Health. 2023;11:e1412–21.

5. World Health Organization. Global Tuberculosis Report 2021. Geneva.

6. Methods used by WHO to estimate the global burden of TB disease. https://www.who.int/publications/m/item/methods-used-by-who-to-estimate-the-global-burden-of-tb-disease-2022. Accessed 7 Feb 2025.

7. Nguyen TS. An Overview of Strategies and Response to the COVID-19 Pandemic in Vietnam. J Epidemiol. 2024;34:605–8.

8. Ragonnet R, Williams BM, Largen A, Nasa J Jr, Jack T, Langinlur MK, et al. Estimating the long-term effects of mass screening for latent and active tuberculosis in the Marshall Islands. Int J Epidemiol. 2022;:dyac045.

9. Completed results of the 2019 Viet Nam population and housing census – General Statistics Office of Vietnam. https://www.gso.gov.vn/en/data-and-statistics/2020/11/completed-results-of-the-2019-viet-nam-population-and-housing-census/. Accessed 30 May 2024.

10. TB profile. https://worldhealthorg.shinyapps.io/tb_profiles/?_inputs_&entity_type=%22country%22&iso2=%22AF%22&lan=%22EN%22. Accessed 30 May 2024.

11. Nguyen HV, Tiemersma EW, Nguyen HB, Cobelens FGJ, Finlay A, Glaziou P, et al. The second national tuberculosis prevalence survey in Vietnam. PLOS ONE. 2020;15:e0232142.

12. Nguyen HV, Nguyen HB, Nguyen NV, Cobelens F, Finlay A, Dao CH, et al. Decline of Tuberculosis Burden in Vietnam Measured by Consecutive National Surveys, 2007–2017. Emerg Infect Dis. 2021;27:872–9.

13. Vehtari A, Gelman A, Gabry J. Practical Bayesian model evaluation using leave-one-out cross-validation and WAIC. Stat Comput. 2017;27:1413–32.

14. Summer documentation — Summer2 documentation. https://summer2.readthedocs.io/en/latest/. Accessed 4 Jun 2024.

15. DEMetropolis(Z) Sampler Tuning. PyMC.
https://www.pymc.io/projects/examples/samplers/DEMetropolisZ_tune_drop_fraction.html.
Accessed 6 Sep 2024.

16. Trauer JM, Hughes AE, Shipman DS, Meehan MT, Henderson AS, McBryde ES, et al. A Data
Science Pipeline Applied to Australia's 2022 COVID-19 Omicron Waves. Infect Dis Model. 2024.
https://doi.org/10.1016/j.idm.2024.08.005.

17. Hoa NB, Sy DN, Nhung NV, Tiemersma EW, Borgdorff MW, Cobelens FG. National survey of
tuberculosis prevalence in Viet Nam. Bull World Health Organ. 2010;88:273–80.

18. Ding C, Hu M, Guo W, Hu W, Li X, Wang S, et al. Prevalence trends of latent tuberculosis
infection at the global, regional, and country levels from 1990–2019. Int J Infect Dis. 2022;122:46–
62.

19. Verkuijl S, Bastard M, Brands A, Viney K, Masini T, Mavhunga F, et al. Global reporting on TB
in children and adolescents: how far have we come and what remains to be done? IJTLD Open.
2024;1:3–6.

20. First-Ever Targeted Roadmap Outlines Steps to End Childhood TB Deaths.
https://www.who.int/vietnam/news/feature-stories/detail/first-ever-targeted-roadmap-outlines-steps-
to-end-childhood-tb-deaths. Accessed 27 May 2025.

21. Kessel B, Heinsohn T, Ott JJ, Wolff J, Hassenstein MJ, Lange B. Impact of COVID-19 pandemic
and anti-pandemic measures on tuberculosis, viral hepatitis, HIV/AIDS and malaria–A systematic
review. PLOS Glob Public Health. 2023;3:e0001018.

22. Marco MH, Ahmedov S, Castro KG. The global impact of COVID-19 on tuberculosis: A thematic
scoping review, 2020–2023. PLOS Glob Public Health. 2024;4:e0003043.

23. Hasan T, Nguyen VN, Nguyen HB, Nguyen TA, Le HTT, Pham CD, et al. Retrospective Cohort
Study of Effects of the COVID-19 Pandemic on Tuberculosis Notifications, Vietnam, 2020. Emerg
Infect Dis. 2022;28:684–92.

24. Innes AL, Lebrun V, Hoang GL, Martinez A, Dinh N, Nguyen TTH, et al. An Effective Health
System Approach to End TB: Implementing the Double X Strategy in Vietnam. Glob Health Sci
Pract. 2024;12:e2400024.

25. Dinh LV, Vo LNQ, Wiemers AMC, Nguyen HB, Vu HQ, Mo HTL, et al. Ensuring Continuity of
Tuberculosis Care during Social Distancing through Integrated Active Case Finding at COVID-19
Vaccination Events in Vietnam: A Cohort Study. Trop Med Infect Dis. 2024;9:26.

26. Storla DG, Yimer S, Bjune GA. A systematic review of delay in the diagnosis and treatment of
tuberculosis. BMC Public Health. 2008;8:15.

27. Teo AKJ, Singh SR, Prem K, Hsu LY, Yi S. Duration and determinants of delayed tuberculosis
diagnosis and treatment in high-burden countries: a mixed-methods systematic review and meta-
analysis. Respir Res. 2021;22:251.

28. Significant Difference of Clinical Manifestations between Smear Negative and Smear Positive
Pulmonary Tuberculosis - CHEST. https://journal.chestnet.org/article/S0012-
3692%2816%2946766-8/fulltext?utm_source=chatgpt.com. Accessed 23 May 2025.

29. Assefa DG, Bedru A, Zeleke ED, Negash SE, Debela DT, Molla W, et al. Efficacy and safety of
different regimens in the treatment of patients with latent tuberculosis infection: a systematic review
and network meta-analysis of randomized controlled trials. Arch Public Health. 2023;81:82.

30. Dale KD, Karmakar M, Snow KJ, Menzies D, Trauer JM, Denholm JT. Quantifying the rates of
late reactivation tuberculosis: a systematic review. Lancet Infect Dis. 2021;21:e303–17.

31. Mirzazadeh A, Kahn JG, Haddad MB, Hill AN, Marks SM, Readhead A, et al. State-level
prevalence estimates of latent tuberculosis infection in the United States by medical risk factors,
demographic characteristics and nativity. PloS One. 2021;16:e0249012.

32. Marks Guy B., Nguyen Nhung V., Nguyen Phuong T.B., Nguyen Thu-Anh, Nguyen Hoa B., Tran
Khoa H., et al. Community-wide Screening for Tuberculosis in a High-Prevalence Setting. N Engl J
Med. 2019;381:1347–57.

Figure 1. Model structure. *Boxes represent different compartment types: Susceptible (S),*

Early latent infection (E), Late latent (L), Active TB (I), Treatment (T) and Recovered (R). Subscripts

indicate stratification by age (a) and pulmonary/smear status (f).

Alt text: The image depicts a compartmental model structure used in epidemiology. It consists of

several boxes representing different disease states, including Susceptible (S), Early latent Infection

(E), Late latent (L), Active TB (I), Treatment (T), and Recovered (R). Each box is further stratified by

age (indicated by subscript 'a') and pulmonary/smear status (indicated by subscript 'f'), illustrating

the transitions and interactions between these different states in the model.

Figure 2. **Model fits to the historical profile of case notifications under our four candidate**

assumptions regarding the effect of COVID-19 on *M.tb* dynamics. *Solid lines represent median*

model estimates. Shaded areas show corresponding interquartile ranges (dark shade) and 95%

credible intervals (light shade). ***Assumption 1:*** *The COVID-19 pandemic had no impact on TB case*

detection or transmission. ***Assumption 2:*** *Only case detection was reduced.* ***Assumption 3:*** *Only*

TB transmission was reduced. ***Assumption 4:*** *Both case detection and TB transmission were*

reduced, incorporating effects from both social distancing and healthcare disruption.

Alt text: Figure 2 shows the model's fit to historical case notifications under four different

assumptions about COVID-19's impact on tuberculosis dynamics. The model's median estimates

are shown by solid lines, while the 95% credible intervals and interquartile ranges are shown by

shaded areas (dark and light, respectively). Assumption 1, neither TB case detection nor

transmission was impacted by the COVID-19 pandemic; Assumption 2, only case detection was

decreased; Assumption 3, only TB transmission was decreased; and Assumption 4, decreases in

both case detection and TB transmission.

Figure 3. Comparison between outputs and empiric observation targets other than annual

case notifications for Vietnam, under the best-fitting candidate model configuration

(Assumption 2). *Model predictions are represented as median (solid line), interquartile credible*

interval (dark blue shade) and 95% central credible interval (light blue shade). Red points and

vertical line (where available) show the point estimates and confidence interval for each calibration

target, while purple points indicate estimates from literature that are presented for comparison but

were not used as calibration targets. Legends indicate the data source for each target.

Alt text: Figure 3 illustrates a comparison between model outputs and empirical observation targets

for Vietnam, excluding annual case notifications, under the best-fitting candidate model

configuration (Assumption 2). The median is represented by a solid line, the interquartile credible

interval by a dark blue line, and the 95% credible interval (CrI) by a light blue line. Red points with

vertical lines that, when available, display the confidence intervals are used to indicate calibration

targets. Estimates from the literature that are utilised for comparison but not as calibration

objectives are shown by purple points. The legend provides specifics about each target's data

source.

Figure 4. Impact of the COVID-19 pandemic on the cumulative number of TB episodes and

TB-related deaths from 2021 to 2035 compared to a counterfactual scenario that COVID-19

had no effect on TB notifications. *Projections made under Assumption 2; values are presented*

on a logarithmic scale. Cumulative diseased: cumulative new TB episodes, Cumulative deaths:

cumulative number of TB-related deaths. Lines indicate the 95% credible intervals of the estimates.

Alt text: Figure 4 displays the impact of the COVID-19 pandemic on the cumulative number of

tuberculosis (TB) episodes and TB-related deaths from 2021 to 2035, compared to a counterfactual

scenario where COVID-19 had no effect on TB notifications. Assumption 2 is used to make the

projections, and a logarithmic scale is used to display the data. The graph labels "Cumulative

deaths" and "Cumulative diseased" denote the total number of TB-related deaths and cumulative

new TB cases, respectively. The graph's lines show the estimations' 95% credible intervals.

Figure 5. Number of cumulative new TB episodes and TB-related deaths averted under two

scenarios of enhancing case detection comparing to *'status quo' scenario*. *Projections made*

under Assumption 2, values are presented on a logarithmic scale. The 'status quo' scenario

assumes case detection remains unchanged. Scenario 1 models a 2-fold increase and Scenario 2

models a 5-fold increase in the rate at which persons with active TB commence care. Lines indicate

the 95% credible intervals of the estimates.

Alt text: The number of cumulative new TB episodes and TB-related deaths prevented under two

scenarios that improve case detection in comparison to a "status quo scenario" is displayed in

Figure 5. The results are displayed on a logarithmic scale, and the projections are made under

Assumption 2. In the 'status quo' scenario, case detection is assumed to stay constant. The rate at

which people with active TB start receiving care is predicted to increase by two times in Scenario 1

and five times in Scenario 2. The graph's lines show the 95% credible intervals of the estimates.

Reference: COVID-19 had no effect on TB notifications

Cumulative number of new TB episodes   Cumulative TB-related deaths

Reference: *Status-quo* scenario

Cumulative number of new TB episodes   Cumulative TB-related deaths